Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for c…
The bill amends section 1860D–14C(g)(2) of the Social Security Act to exclude certain orally administered drugs from the Medicare Part D manufacturer discount program. The exclusion applies to orally administered drugs approved via a new drug application (NDA) and granted a narrow CMS exception reclassifying them as noninnovator multiple source drugs under the Medicaid rebate program.
Progressives emphasize higher beneficiary costs; conservatives emphasize reduced regulatory burden.
Relative to its intended legislative type, this bill is a narrow substantive amendment to the Medicare statute that adds an explicit exclusion for certain orally administered drugs from the Part D manufacturer discount program; the statutory language is specific about the eligibility criteria but omits ancillary implementation, fiscal, and oversight details.
The bill amends section 1860D–14C(g)(2) of the Social Security Act to exclude certain orally administered drugs from the Medicare Part D manufacturer discount program.
The exclusion applies to orally administered drugs approved via a new drug application (NDA) and granted a narrow CMS exception reclassifying them as noninnovator multiple source drugs under the Medicaid rebate program.
The change is narrowly targeted to that reclassification exception.
Narrow, implementable change but politically sensitive area, unclear fiscal offsets, and limited compromise elements reduce chances.
Relative to its intended legislative type, this bill is a narrow substantive amendment to the Medicare statute that adds an explicit exclusion for certain orally administered drugs from the Part D manufacturer discount program; the statutory language is specific about the eligibility criteria but omits ancillary implementation, fiscal, and oversight details.
Progressives emphasize higher beneficiary costs; conservatives emphasize reduced regulatory burden.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize higher beneficiary costs; conservatives emphasize reduced regulatory burden.
Likely skeptical and broadly opposed.
They would read this as a targeted carve‑out that reduces manufacturer discount obligations under Part D and could raise beneficiary costs and weaken bargaining leverage.
They may acknowledge narrow access benefits but view overall effects as favoring manufacturers over patients.
Mixed view.
Sees the bill as a narrow technical fix addressing a regulatory inconsistency, but worries about cost and precedent.
Would look for data, budget impacts, and safeguards before supporting it.
Generally favorable.
Views the bill as reducing an onerous manufacturer obligation and removing a regulatory disincentive that can limit access.
Emphasizes reduced regulatory burden and potential improved availability of orally administered drugs.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Narrow, implementable change but politically sensitive area, unclear fiscal offsets, and limited compromise elements reduce chances.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize higher beneficiary costs; conservatives emphasize reduced regulatory burden.
Narrow, implementable change but politically sensitive area, unclear fiscal offsets, and limited compromise elements reduce chances.
Relative to its intended legislative type, this bill is a narrow substantive amendment to the Medicare statute that adds an explicit exclusion for certain orally administered drugs from the Part D manufacturer discount…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.